Drug Trial Radar · NCT05786924
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
623
Planned (sponsor's estimate)
Start
Apr 18, 2023
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Institut de Recherches Internationales ServierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC, GI tumors (including ColoRectal Cancer (CRC), and non-CRC GI adenocarcinoma, and Biliary Tract Cancer (BTC)) with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28 or 21-days cycles (depending on the study part they are included in) until disease progression, toxicity, withdrawal of consent, or termination of the study.
Conditions
- Non-small Cell Lung Cancer
- Histiocytic Neoplasm
- Histiocytosis
- BRAF Gene Mutation
- BRAF V600E
- BRAF V600 Mutation
- BRAF Mutation-Related Tumors
- BRAF
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Lung Cancer
- Recurrent Lung Cancer
- Recurrent Lung Non-Small Cell Carcinoma
- NSCLC
- Solid Tumor
- Solid Carcinoma
- KRAS G12D
- KRAS G12V
- KRAS Mutation-Related Tumors
- NRAS Gene Mutation
- Thyroid Cancer
- Thyroid Carcinoma
- Colorectal Cancer
- Colorectal Carcinoma
- Recurrent Histiocytic and Dendritic Cell Neoplasm
- Brain Metastases
- Recurrent NSCLC
- KRAS G13C
- Acquired Resistance to KRAS G12C Inhibitor
- KRAS G12A
- KRAS G12F
- KRAS G12R
- KRAS G13D
Interventions
S241656Drug
RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations
FOLFOX6/FOLFOX7Drug
Used as a combination therapy and administered intravenously
FOLFIRIDrug
Used as a combination therapy and administered intravenously
CetuximabDrug
Used as a combination therapy and administered intravenously
PanitumumabDrug
Used as a combination therapy and administered intravenously
TrametinibDrug
Used as a combination therapy and administered orally
PembrolizumabDrug
Used as a combination therapy and administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Incidence of dose-limiting toxicities (DLTs)Time frame: The first 28-day cycle (Cycle 1)
- Dose Escalation: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Through study completion, approximately 5 years
- Dose Optimization/Expansion: Objective response (OR)Time frame: Through study completion, approximately 5 years
Locations
49 sites in 10 countries. Site status is shown where the registry gives one.
Banner Health- MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
The Angeles clinic - A cedars SINAI AFFILIATE
Los Angeles, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
University of California, San Francisco (UCSF)
San Francisco, California · Recruiting
University of Colorado - Aurora Cancer Center
Aurora, Colorado · Not yet recruiting
Yale University School of Medicine - Yale Cancer Center
New Haven, Connecticut · Recruiting
Georgetown University Lombardi Cancer Center
Washington D.C., District of Columbia · Not yet recruiting
Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan · Recruiting
Masonic Cancer Center University of Minnesota
Minneapolis, Minnesota · Recruiting
Washington University
St Louis, Missouri · Recruiting
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute)
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke University School of Medicine
Durham, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Sarah Canon Research Institute (SCRI) Oncology Partners
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
START San Antonio
San Antonio, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Peter MacCallum Cancer Centre
East Melbourne, Australia · Not yet recruiting
Westmead Hospital
Westmead, Australia · Not yet recruiting
Beijing Cancer Hospital
Beijing, China · Recruiting
Shandong Cancer Hospital (Cancer Hospital of Shandong First Medical University)
Jinan, China · Recruiting
Fudan University Zhongshan Hospital
Shanghai, China · Not yet recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, China · Recruiting
Center for Cancer and Organ Diseases - Rigshospitalet
Copenhagen, Denmark · Recruiting
Centre Georges Francois Leclerc
Dijon, France · Not yet recruiting
Institut Curie
Paris, France · Recruiting
AP-HP Hopital Europeen Georges Pompidou
Paris, France · Recruiting
Centre Eugene Marquis
Rennes, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Not yet recruiting
Queen Mary Hospital
Hong Kong, Hong Kong · Recruiting
Prince of Wales
Shatin, Hong Kong · Recruiting
Istituto Europeo di Oncologia
Milan, Italy · Not yet recruiting
IFO - Istituto Nazionale dei Tumori Regina Elena
Rome, Italy · Not yet recruiting
Istituto Clinico Humanitas
Rozzano, Italy · Recruiting
Kanagawa Cancer Center
Kanagawa, Japan · Recruiting
Kyoto University Hospital
Kyoto, Japan · Recruiting
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.